Note: Descriptions are shown in the official language in which they were submitted.
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
microRNA inhibitors for use in treating metabolic diseases
The present invention relates to a composition comprising an inhibitor of miR-
379 or a
portion or fragment thereof and an inhibitor of miR-541 or a portion or
fragment thereof,
and/or an inhibitor of the target site of miR-379 or a portion or fragment
thereof and an
inhibitor of the target site of miR-541 or a portion or fragment thereof,
and/or a combination
of an inhibitor of miR-379 or a portion or fragment thereof and an inhibitor
of the target site of
miR-541 or a portion or fragment thereof or a combination of an inhibitor of
the target site of
miR-379 or a portion or fragment thereof and an inhibitor of miR-541 or a
portion or fragment
thereof. The present invention further relates to such compositions for use in
treating or
preventing a metabolic disease, a disease related to a metabolic disorder,
and/or cancer.
Metabolic dysfunctions and diseases are often associated with a disbalanced
level of
glucocorticoid hormones and are associated with conditions such as, e.g.,
fasting, cancer
cachexia, aging, Cushing's syndrome, GC therapy, obesity, insulin resistance,
diabetes type
1 and 2, hyperglycemia, dyslipidemia, HCC (hepatocellular cancer), and others.
For
example, the metabolic syndrome (a constellation of metabolic disorders that
all result from,
or are associated with, a primary disorder of insulin resistance) is
characterized by a group of
metabolic risk factors including abdominal obesity, elevated triglyceride
levels, decreased
high density lipoprotein (HDL) cholesterol levels, high blood pressure, and
impaired fasting
blood glucose (a measure for decreased insulin sensitivity and increased risk
of developing
diabetes). Patients suffering from such conditions and diseases are at
increased risk of
coronary heart disease and other atherosclerotic conditions such as stroke and
peripheral
vascular disease and diabetes type 2.
The hypothalamic-pituitary-adrenal (HPA) endocrine axis is a critical
physiological stress
circuit to maintain body homeostasis during diverse situations such as trauma,
exercise or
nutrient deprivation. In metabolic control, GC signaling acts as a major
counter-regulatory
system against insulin action, and aberrantly elevated GC activity is tightly
linked to major
components of the Metabolic Syndrome, including obesity, insulin resistance,
hyperglycemia,
and systemic dyslipidemia. Indeed, GC levels have been found to be elevated in
insulin-
resistant patients and are strongly associated with a hyperglycemic and fatty
liver phenotype,
mediated through the glucocorticoid receptor (GR), a member of the nuclear
receptor
1
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
transcription factor family. In congruence, obesity is characterized by
enhanced local GC
action, and states of either endogenous or exogenous GC deficiency or excess,
e.g.
Addison's disease, Cushing's syndrome, or GC therapy, respectively, are
characterized by
severe perturbations in systemic energy metabolism that closely mimic aspects
of the
Metabolic Syndrome.
A class of small non-coding RNAs (microRNAs, also referred to herein as miRNAs
or miRs)
has emerged as a critical layer of metabolic control. MicroRNAs (miRNAs, miRs)
are a class
of small (e.g., 18-24 nucleotides) non-coding RNAs that exist in a variety of
organisms,
including mammals, and are conserved in evolution. miRNAs are processed from
hairpin
precursors of about 70 nucleotides, which are derived from primary transcripts
through
sequential cleavage by RNAse III enzymes. Many microRNAs can be encoded in
intergenic
regions, hosted within introns of pre-mRNAs or within non-coding RNA genes.
Many miRNAs
also tend to be clustered and transcribed as polycistrons and often have
similar spatial
temporal expression patterns. miRs have been found to have roles in a variety
of biological
processes including developmental timing, differentiation, apoptosis, cell
proliferation, organ
development, and metabolism. Indeed, individual miRNA have been found to
regulate
diverse aspects of energy homeostasis, including pancreatic beta cell insulin
secretion,
adipose tissue lipid storage, and hepatic cholesterol and lipid handling.
Also, some miRNAs
such as miR-379 have been identified to be involved in glucocorticoid (GC)
signaling (WO
2015/063081). For example, inhibition of miR-379 activity was shown to lower
circulating
triglyceride (TG) levels (de Guia etal., EMBO J (2015), 34(3): 344-360).
However, metabolic
dysfunctions and diseases are still not yet treatable in a sufficient manner
and suitable
therapies for such diseases including diabetes type 1 and 2 are desirable.
The present invention addresses these needs and objectives by providing
solutions as
described herein and as defined in the claims.
As shown before in animal studies, inhibition of miR-379 activity leads to
lower circulating
triglyceride (TG) levels (de Guia et al., EMBO J (2015), 34(3): 344-360). As
has further been
found in context with the present invention, another miRNA, i.e. miRNA-541
(miR-541), was
found to be overexpressed in obese patients, identifying a correlation of miR-
541 with insulin
sensitivity (cf. Table 1). However, inhibition or knock-down of miR-541 did
not lead to a
substantial metabolic phenotype (data not shown). Yet, as has surprisingly
been found in
context with the present invention and shown herein, simultaneous inhibition
of both, miR-
379 and miR-541 improves both, glucose and lipid metabolism by lowering TG and
glucose
2
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
levels. This surprising finding leads to the current invention where both, miR-
379 and miR-
541 are inhibited, allowing treatment of disorders and diseases correlated
with glucose and
lipid metabolism, including, but not limited to, glucocorticoid hormone driven
metabolic
dysfunction, obesity, diabetes (including type 1 and 2), diabesity, metabolic
syndrome, insulin
resistance, hyperglycemia, (systemic) dyslipidemia, Cushing's syndrome,
adverse or side
effects associated with or caused by glucocorticoid (GC) treatment or excess,
atherosclerosis, heart disease, stroke, (cancer) cachexia, and growth defects,
hepatic
steatosis, NASH, and liver fibrosis, particularly diabetes type 1 and 2,
including personalized
treatment of diabetes type 1 and 2.
Thus, the present invention relates to a composition comprising
(a) an inhibitor of miR-379 or a portion or fragment thereof and an
inhibitor of miR-541 or
a portion or fragment thereof, and/or
(b) an inhibitor of the target site of miR-379 or a portion or fragment
thereof and an
inhibitor of the target site of miR-541 or a portion or fragment thereof,
and/or
(c) a combination of an inhibitor of miR-379 or a portion or fragment
thereof and an
inhibitor of the target site of miR-541 or a portion or fragment thereof or a
combination
of an inhibitor of the target site of miR-379 or a portion or fragment thereof
and an
inhibitor of miR-541 or a portion or fragment thereof.
As used herein, the term "target site" is the site within mRNA of a cell,
which is normally
targeted by the miRNA in order to suppress or inhibit translation of that
mRNA, to allow
cleavage of that mRNA, or to destabilize that mRNA to allow accelerated
degradation (also
known to the skilled person as "silencing" of the mRNA). Consequently, the
term "inhibitor of
the target site" means in the context of the present invention an inhibitor of
such "target site"
as defined above. Thus, the composition as described and provided in context
with the
present invention may comprise an inhibitor of miR-379 or a portion or
fragment thereof and
of miR-541 or a portion or fragment thereof, and/or of the respective target
sites of said
miRs, thus preventing the miRs from docking to the target site to silence the
respective
mRNA. As readily understood by the skilled person, such inhibitor of a target
site of miR-379
or a portion or fragment thereof or of miR-541 or a portion or fragment
thereof does not
interfere with proper translation of the respective mRNA and does not cleave
or destabilize
said mRNA, or at least to a lower extent compared to the respective miR-379 or
a portion or
fragment thereof or miR-541 or a portion or fragment thereof itself.
3
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
Furthermore, as used herein, the term "microRNA", "miRNA" or "miR" are used
interchangeably and typically comprise non-coding RNA between 18 and 26
nucleobases in
length, which may be the product of cleavage of a pre-miRNA by the enzyme
Dicer.
Examples of mature miRNAs are found in a miRNA database known in the art such
as
miRBase (http://microma.sangerac.uk/).
Furthermore, as used herein, the term "inhibiting" or "inhibitor of" miR-379
or miR-541 (or of
the respective target site) or a portion or fragment thereof, respectively,
comprises that the
binding or docking between miR-379 or a portion or fragment thereof or miR-541
or a portion
or fragment thereof to its respective target site is inhibited or suppressed,
e.g., either by
directly binding the respective miR or its target site, or by supporting or
inducing cleavage or
degradation of miR-379 or miR-541, or otherwise impairing the function and/or
expression of
miR-379 or a portion or fragment thereof or of miR-541 or a portion or
fragment thereof,
respectively. For example, the inhibitor may be or comprise a nucleic acid
molecule. In one
aspect of the present invention, the inhibitor of miR-379 or a portion or
fragment thereof
and/or of miR-541 or a portion or fragment thereof may serve as an antisense
molecule to
the respective miR.
In context of the present invention, the inhibitor of miR-379 or a portion or
fragment thereof
and the inhibitor of miR-541 or a portion or fragment thereof as comprised by
the
composition described and provided herein may be in the same molecule or on
different
molecules. For example, the composition of the present invention may comprise
a nucleic
acid molecule comprising both, a sequence serving as inhibitor of miR-379 or a
portion or
fragment thereof, and a sequence serving as inhibitor of miR-541 or a portion
or fragment
thereof, or it may comprise two different nucleic acid molecules, one
comprising a sequence
serving as inhibitor of miR-379 or a portion or fragment thereof, and the
other one comprising
a sequence serving as inhibitor of miR-541 or a portion or fragment thereof.
In one
embodiment of the present invention, the composition comprises an inhibitor of
miR-379 or a
portion or fragment thereof and an inhibitor of miR-541 or a portion or
fragment thereof on
the same molecule, wherein said molecule comprises both, a nucleotide sequence
complementary to or hybridizing as described herein (e.g., under stringent
conditions) to
miR-379 or a portion or fragment thereof and a nucleotide sequence
complementary to or
hybridizing as described herein (e.g., under stringent conditions) to miR-541
or a portion or
fragment thereof.
4
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
Generally, as used herein, the terms õpolynucleotide", õnucleic acid" or
õnucleic acid
molecule" are to be construed synonymously. Generally, nucleic acid molecules
may
comprise inter alia DNA molecules, RNA molecules, oligonucleotide
thiophosphates,
substituted ribo-oligonucleotides or PNA molecules. Furthermore, the term
"nucleic acid
molecule" may refer to DNA or RNA or hybrids thereof or any modification
thereof that is
known in the art (see, e.g., US 5525711, US 471 1955, US 5792608 or EP 302175
for
examples of modifications). The polynucleotide sequence may be single- or
double-
stranded, linear or circular, natural or synthetic, and without any size
limitation. For instance,
the polynucleotide sequence may be genomic DNA, cDNA, mitochondrial DNA, mRNA,
antisense RNA, ribozymal RNA or a DNA encoding such RNAs or chimeroplasts
(Gamper,
Nucleic Acids Research, 2000, 28, 4332 - 4339). Said polynucleotide sequence
may be in
the form of a vector, plasmid or of viral DNA or RNA. Also described herein
are nucleic acid
molecules, which are complementary to the nucleic acid molecules described
above and
nucleic acid molecules, which are able to hybridize to nucleic acid molecules
described
herein. A nucleic acid molecule described herein may also be a fragment of the
nucleic acid
molecules in context of the present invention. Particularly, such a fragment
is a functional
fragment. Examples for such functional fragments are nucleic acid molecules,
which can
serve as primers.
As used herein, nucleic acid molecules may comprise different types of
nucleotides,
comprising naturally occurring nucleotides, modified nucleotides, and
artificial nucleotides.
Nucleotides as used herein generally comprise nucleosides, naturally occurring
nucleosides,
modified nucleosides, and artificial nucleosides. As known in the art,
naturally occurring
nucleosides comprise purin bases or pyrimidin bases. Examples for naturally
occurring
nucleosides comprise (deoxy)adenosine, (deoxy)guanosine, (deoxy)uridine,
thymidine, and
(deoxy)cytidine. Nucleosides as part of nucleotides (and, thus, nucleic acid
molecules) as
described herein may generally encompass structures comprising any purine or
pyrimidine
nucleoside and derivatives or analogues thereof. That is, "purine nucleoside"
or "pyrimidine
nucleoside" as used in context with the present invention generally comprises
any kind of
purine or pyrimidine as well as derivatives or analogues thereof as described
herein
respectively, as well as a sugar, e.g., a pentose. In one embodiment of the
present invention,
the purine nucleoside may be selected from the group consisting of
(deoxy)adenosine,
inosine, and (deoxy)guanosine and derivatives or analogues thereof. A
derivative may be,
e.g., a nucleoside with a purine selected from the group consisting of a
deazapurine, an
azidopurine, an alkylpurine, a thiopurine, a bromopurine, an 0-alkylpurine,
and an isopurine,
for example, a deazapurine such as, e.g., 7-deazapurine. That is, in one
aspect of the
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
present invention, the purine nucleoside may be a nucleoside with a purine
selected from the
group consisting of a deazapurine, an azidopurine, an alkylpurine, a
thiopurine, a
bromopurine, an 0-alkylpurine, and an isopurine, for example a deazapurine
such as, e.g., 7-
deazapurine. In another aspect of the present invention, the purine nucleoside
may be
selected from the group consisting of 1-methyl-(deoxy)adenosine, 2-methyl-
(deoxy)adenosine, N6-methyl-(deoxy)adenosine, N6,N6-dimethyl-(deoxy)adenosine,
7-deaza-
(deoxy)adenosine, 7-deaza-8-aza(deoxy)adenosine, 7-deaza-7-
bromo(deoxy)adenosine, 7-
deaza-7-iodo(deoxy)adenosine, 8-azido(deoxy)adenosine, 8-
bromo(deoxy)adenosine, 8-
iodo(deoxy)adenosine, 8-bromo-2'-deoxy(deoxy)adenosine, 2'-0-methyladenosin,
inosin, 1-
methylinosin, 2'-0-methylinosin, 1-methyl(deoxy)guanosine, 7-
methyl(deoxy)guanosine, N2-
methyl(deoxy)guanosine, N2,N2-dimethyl-guanosine,
isoguanosine, 7-
deaza(deoxy)guanosine, 7-deaza-8-aza(deoxy)guanosine, 7-
deaza-7-
bromo(deoxy)guanosine, 7-deaza-7-iodo(deoxy)guanosine, 6-thio(deoxy)guanosine,
06-
methyl(deoxy)guanosine, 8-azido(deoxy)guanosine, 8-
bromo(deoxy)guanosine, 8-
iodo(deoxy)guanosine, 2'-0-methylguanosine, 8-azidoinosine, 7-azainosine, 8-
bromoinosine,
8-iodoinosine, 1-methylinosine, and 4-methylinosine. In a further aspect of
the present
invention, the purine nucleosides may be selected from the group consisting of
a queuosine,
an archaeosine, a wyosine and a N6-threonylcarbamoyladenosine. In one aspect
of the
present invention, the pyrimidine nucleoside may be selected from the group
consisting of
(deoxy)cytidine, (deoxy)thym id ine, (deoxy)ribothymidine, (deoxy)uridine, and
derivatives
thereof. A derivative may be, e.g., a nucleoside with a pyrimidine selected
from the group
consisting of an alkylpyrimidine, a thiopyrimidine, a bromopyrimidine, an 0-
alkylpyrimidine,
an isopyrimidine, an acetylpyrimidine hydropyrimidine, and a pseudopyrimidine.
That is, in
one aspect of the present invention, the pyrimidine nucleoside may be a
nucleoside with a
pyrimidine selected from the group consisting of an alkylpyrimidine, a
thiopyrimidine, a
bromopyrimidine, an 0-alkylpyrimidine, an isopyrimidine, an acetylpyrimidine
hydropyrimidine, and a pseudopyrimidine. In another aspect of the present
invention, the
pyrimidine nucleoside may be selected from the group consisting of 3-methyl-
(deoxy)cytidine, N4-methyl(deoxy)cytidine, N4,N4-dimethyl(deoxy)cytidine,
iso(deoxy)cytidine,
pseudo(deoxy)cytidine, pseudoiso(deoxy)cytidine, 2-
thio(deoxy)cytidine, N4-
acetyl(deoxy)cytidine, 3-methyl(deoxy)uridine,
pseudo(deoxy)uridine, 1 -methyl-
pseudo(deoxy)uridine, 5,6-dihydro(deoxy)uridine, 2-thio(deoxy)uridine, 4-
thio(deoxy)uridine,
5-bromodeoxy(deoxy)uridine, 2'-deoxyuridine, 4-
thio(deoxy)thymidine, 5,6-
dihydro(deoxy)thymidine, 04-methylthymidine, difluortoluene, and other
nucleobase
surrogates. As mentioned, the nucleosides as described and provided herein
generally
comprise a purine or pyrimidine or derivative or analogue thereof as described
herein as well
6
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
as sugar moiety such as, e.g., a pentose. Generally, the pentose as part of
the purine or
pyrimidine nucleoside or derivative or analogue thereof as described herein
may be, inter
alia, ribose, deoxyribose, arabinose, or methylribose (2-0-methyribose), for
example, a
ribose or a deoxyribose. That is, the nucleoside may be, e.g., a
(ribosyl)nucleoside, a
desoxy(ribosyl)nucleoside, an arabinosylnucleoside or an
(methylribosyl)nucleoside, for
example a (ribosyl)nucleoside or a deoxy(ribosyl)nucleoside.
As used herein, the terms "desoxy" and "deoxy" as prefixes of molecule terms
are used
synonymously and indicate the absence of an oxygen atom or a hydroxyl-group,
e.g., in a
given pentose such as ribose or others.
In one aspect of the present invention, the inhibitor of miR-379 and/or miR-
541 or a portion
or fragment thereof, respectively, may serve as an antisense molecule to the
respective miR.
In one embodiment of the present invention, at least one (or all) inhibitor(s)
of miR-379 or a
portion or fragment thereof comprise(s) a nucleotide sequence complementary to
or
hybridizing (e.g., under stringent conditions) to miR-379 or a portion or
fragment thereof, and
at least one (or all) inhibitor(s) of miR-541 or a portion or fragment thereof
comprises a
nucleotide sequence complementary to or hybridizing (e.g., under stringent
conditions) to
miR-541 or a portion or fragment thereof. In this context, it is possible that
the inhibitor of
miR-379 or a portion or fragment thereof and the inhibitor of miR-541 or a
portion or fragment
thereof are located on different molecules, or they may be located on a single
molecule, i.e.
one molecule comprises both, an inhibitor of miR-379 or a portion or fragment
thereof and an
inhibitor of miR-541 or a portion or fragment thereof. In one embodiment of
the present
invention, the inhibitor of miR-379 or a portion or fragment thereof and the
inhibitor of miR-
541 or a portion or fragment thereof are located on a single molecule.
The term "hybridization" or "hybridizes" as used herein in context with
inhibitors and nucleic
acid molecules/DNA sequences incl. miRs or a portion or fragment thereof may
relate to
hybridizations under stringent, low stringent or non-stringent conditions. In
one embodiment,
the conditions are preferably stringent. Said hybridization conditions may be
established
according to conventional protocols described, for example, in Sambrook,
Russell "Molecular
Cloning, A Laboratory Manual", Cold Spring Harbor Laboratory, N. Y. (2001);
Current
Protocols in Molecular Biology, Update May 9, 2012, Print ISSN: 1934-3639,
Online ISSN:
1934-3647; Ausubel, "Current Protocols in Molecular Biology", Green Publishing
Associates
and Wiley Interscience, N. Y. (1989), or Higgins and Hames (Eds.), "Nucleic
acid
hybridization, a practical approach", IRL Press Oxford, Washington DC, (1985).
The setting
7
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
of conditions is well within the skill of the artisan and can be determined
according to
protocols described in the art. Thus, the detection of only specifically
hybridizing sequences
will usually require stringent hybridization and washing conditions such as
0.1 x SSC, 0.1%
SDS at 65 C ("stringent conditions" as used herein). Non-stringent
hybridization conditions
for the detection of homologous or not exactly complementary sequences may be
set at 6 x
SSC, 1% SDS at 65 C ("non-stringent conditions" as used herein). As is well
known, the
length of the probe and the composition of the nucleic acid to be determined
constitute
further parameters of the hybridization conditions. Variations in the above
conditions may be
accomplished through the inclusion and/or substitution of alternate blocking
reagents used to
suppress background in hybridization experiments. Typical blocking reagents
include
Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and
commercially
available proprietary formulations. The inclusion of specific blocking
reagents may require
modification of the hybridization conditions described above, due to problems
with
compatibility. In accordance to the invention described herein, low stringent
hybridization
conditions for the detection of homologous or not exactly complementary
sequences may, for
example, be set at 6 x SSC, 0.5 % SDS at 65 C ("low stringent conditions" as
used herein).
As is well known, the length of the probe and the composition of the nucleic
acid to be
determined constitute further parameters of the hybridization conditions.
Hybridizing nucleic acid molecules also comprise fragments of the above
described
molecules. Such fragments may represent nucleic acid molecules serving as
inhibitors as
described herein or a functional fragment thereof. Furthermore, nucleic acid
molecules,
which hybridize with any of the aforementioned nucleic acid molecules, also
include
complementary fragments, derivatives and variants of these molecules.
Additionally, a
hybridization complex refers to a complex between two nucleic acid sequences
by virtue of
the formation of hydrogen bonds between complementary G and C bases and
between
complementary A and T (or U for RNA as known to the skilled person) bases;
these
hydrogen bonds may be further stabilized by base stacking interactions. The
hydrogen bonds
may be in an antiparallel configuration. A hybridization complex may be formed
in solution
(e.g., Cot or Rot analysis) or between one nucleic acid sequence present in
solution and
another nucleic acid sequence immobilized on a solid support (e.g., membranes,
filters,
chips, pins or glass slides to which, e.g., cells have been fixed). The terms
"complementary"
or "complementarity" refer to the natural binding of polynucleotides under
permissive salt and
temperature conditions by base-pairing. For example, the sequence "A-G-U"
binds to the
complementary sequence "U-C-A". Complementarity between two single-stranded
molecules
may be "partial", in which only some of the nucleic acids bind, or it may be
complete when
8
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
total complementarity exists between single-stranded molecules. The degree of
complementarity between nucleic acid strands has significant effects on the
efficiency and
strength of hybridization between nucleic acid strands. This is of particular
importance in
amplification reactions, which depend upon binding between nucleic acids
strands. The term
"hybridizing sequences" preferably refers to sequences, which display a
sequence identity of
at least 45%, more preferably at least 50%, more preferably at least 55%, more
preferably at
least 60%, more preferably at least 65%, more preferably at least 70%, more
preferably at
least 75%, more preferably at least 80%, more preferably at least 85%, more
preferably at
least 90%, more preferably at least 95%, more preferably at least 96%, more
preferably at
least 97%, more preferably at least 98%, more preferably at least 99%, more
preferably at
least 99.5%, and most preferably 100% identity with a nucleic acid sequence as
described
herein serving as an inhibitor as described and provided herein.
As used herein, a "portion" or "fragment" of a given microRNA (miRNA) may be
any portion
of a microRNA and may particularly comprise portions of a microRNA or
precursor thereof
(e.g., pri- or pre-microRNA) comprising or consisting of at least 10, 11, 12,
13, 14, 15, 16, 17,
18, 19, 20, 21 or 22 consecutive nucleotides of the respective microRNA or
precursor
thereof. In one embodiment, a portion or fragment of a given microRNA is a
portion or
fragment, which prevails in the cell after (nuclear and/or cytoplasmic)
processing of the
microRNA (e.g., pri- or pre-microRNAs), e.g., the 5p-arm (also referred to as
5p-strand) or
3p-arm (also referred to as 3p-strand) of the respective miR. In one
embodiment of the
present invention, a portion or fragment of a microRNA is the 5p-arm of a
microRNA or its
precursor. For example, in accordance with the present invention, a portion or
fragment of
miR-379 may be inter alia miR-379-5p, and/or a portion or fragment of miR-541
may be inter
alia miR-541-5p. In one embodiment of the present invention, a portion or
fragment of a
microRNA is the 3p-arm of a microRNA or its precursor. For example, in
accordance with the
present invention, a portion or fragment of miR-379 may be inter alia miR-379-
3p, and/or a
portion or fragment of miR-541 may be inter alia miR-541-3p.
In this context, as it is readily understood by the person skilled in the art,
and in accordance
with the present invention, an inhibitor of a portion or fragment of a given
microRNA is also
an inhibitor of the microRNA itself or its precursors, as inhibiting the
portion or fragment as
defined herein also inhibits the whole microRNA from its function as defined
herein.
Accordingly, as used herein, an inhibitor of a microRNA (e.g., miR-379 or miR-
541) or its
precursor may also comprise an inhibitor of a portion or fragment of that
microRNA (e.g.,
9
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
miR-379 or miR-541), respectively if that inhibitor binds or is complementary
to or hybridizes
(e.g., under stringent conditions) to that portion or fragment. Likewise, in
accordance with the
present invention, an inhibitor of a portion or fragment of that microRNA
(e.g., miR-379 or
miR-541) also comprises an inhibitor of that respective microRNA (e.g., miR-
379 or miR-541)
or its precursor.
In one embodiment of the present invention, a portion or fragment of miR-379
is miR-379-5p
and has a nucleotide sequence according to SEQ ID NO: 1, wherein not more than
6, 5, 4, 3,
2 or 1 nucleotides are substituted. For example, the nucleotides, which are
substituted
compared to SEQ ID NO: 1 may be any other nucleotide, which allows
hybridization of the
respective inhibitor as described herein. In one embodiment of this invention,
said
substitutions may be located within the last 6, 5, 4, 3, 2 or 1 nucleotides of
the 3'-end of SEQ
ID NO: 1 and/or at the first nucleotide of the 5'-end of SEQ ID NO: 1. In a
specific
embodiment of the present invention, a portion or fragment of miR-379 is miR-
379-5p and
has a nucleotide sequence according to SEQ ID NO: 1.
In a further embodiment of the present invention, a portion or fragment of miR-
541 is miR-
541-5p and has a nucleotide sequence according to SEQ ID NO: 2, wherein not
more than 8,
7, 6, 5, 4, 3, 2 or 1 nucleotides are substituted. For example, the
nucleotides, which are
substituted compared to SEQ ID NO: 2 may be any other nucleotide, which allows
hybridization of the respective inhibitor as described herein. In one
embodiment of this
invention, said substitutions may be located within the last 8, 7, 6, 5, 4, 3,
2 or 1 nucleotides
of the 3'-end of SEQ ID NO: 2 and/or at the first nucleotide of the 5'-end of
SEQ ID NO: 2. In
a specific embodiment of the present invention, a portion or fragment of miR-
541 is miR-541-
5p and has a nucleotide sequence according to SEQ ID NO: 2.
In one embodiment of the composition of the present invention, a portion of
miR-379 has a
nucleotide sequence according to SEQ ID NO: 1, wherein not more than 6
nucleotides are
substituted, and a portion of miR-541 has a nucleotide sequence according to
SEQ ID NO: 2,
wherein not more than 8 nucleotides are substituted.
The inhibitor comprised by the composition described and provided by the
present invention
may be any inhibitor, which is preferably capable of inhibiting or suppressing
the binding or
docking between miR-379 (or a portion or fragment thereof) or miR-541 (or a
portion or
fragment thereof) to its respective target site, e.g., either by directly
binding the respective
miR or its target site, or by supporting or inducing cleavage or degradation
of miR-379 (or a
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
portion or fragment thereof) or miR-541 (or a portion or fragment thereof), or
otherwise
impairing the function and/or expression of miR-379 (or a portion or fragment
thereof) or
miR-541 (or a portion or fragment thereof), respectively. For example, the
inhibitor may be or
comprise a nucleic acid molecule.
In one embodiment of the present invention, at least one inhibitor comprises a
nucleic acid
sequence comprising at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20
nucleotides, for
example at least 15 or 16 nucleotides. In a further embodiment of the present
invention, the
inhibitor does not exceed the length of 250, 200, 150, 140, 130, 120, 110,
100, 90, 80, 70,
60, 50, 45, 40, 35, 30, or 25 nucleotides.
In context with the present invention, the inhibitor of miR-379 (or a portion
or fragment
thereof) and/or miR-541 (or a portion or fragment thereof) may directly target
the respective
miR or portions thereof or fragments thereof as described herein. General
inhibitory
molecules capable of inhibiting a miR are known in the art. In one embodiment
of the present
invention, the inhibitor to miR-379 (or a portion or fragment thereof) and/or
miR-541 (or a
portion or fragment thereof) may be selected from the group consisting of
Tough Decoys
(TuD) (e.g., Tough Decoy RNA), Decoys, antisense oligonucleotides (antisense
RNA or
DNA, chimeric antisense molecules), anti-miR, block-miR, ribozymes, external
guide
sequence (EGS), oligonucleotides, small interference RNA (siRNA), small
temporal RNA
(stRNA), short hairpin RNA (shRNA), small RNA-induced gene activation (RNAa),
small
activating RNA (saRNA), locked nucleic acids (LNA), antagomirs, and peptide
nucleic acids
(PNA) and other oligomeric nucleic acid molecules, which are able to inhibit
or suppress the
function of the respective miR as described herein (e.g., by hybridizing to at
least a portion of
the target site of the respective miR). In a specific embodiment of the
present invention, the
at least one inhibitor is a Tough Decoy RNA (TuD). Tough decoys are generally
known in the
art and available, e.g., from SignaGen Laboratories (USA). In context with
the present
invention, the composition of the present invention may, e.g., comprise a TuD
comprising
both, a sequence inhibiting miR-379 (or a portion or fragment thereof) and
another sequence
inhibiting miR-541 (or a portion or fragment thereof) on the same TuD-
molecule, or the
composition of the present invention may comprise two different TuDs, one
comprising a
sequence inhibiting miR-379 (or a portion or fragment thereof) and the other
one comprising
a sequence inhibiting miR-541 (or a portion or fragment thereof). For example,
the
composition of the present invention comprises a TuD comprising both, a
sequence inhibiting
miR-379 (or a portion or fragment thereof) and another sequence inhibiting miR-
541 (or a
portion or fragment thereof) on the same TuD-molecule. In a specific
embodiment of the
11
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
present invention, said inhibitor comprises the nucleotide sequence of SEQ ID
NO: 5,
wherein not more than 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 nucleotides are
substituted compared to
SEQ ID NO: 5. In a further specific embodiment of the present invention, said
inhibitor is a
nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 5.
Furthermore, the inhibitor comprised by the composition described and provided
herein may
also comprise a chemical modification, e.g., in order to improve stability or
allow proper
administration to a subject in need thereof. In one embodiment of the present
invention, at
least one inhibitor comprises a chemical modification of the nucleic acid
sequence selected
from the group consisting of nucleic acid analogs comprising N-
acetylgalactosamine
(GaINAc), phosphorothioate DNA (PS), 21-0-methyl RNA (0Me), 2'-0-methoxy-ethyl
RNA
(MOE), peptide nucleic acid (PNA), N3'-P5'-phosphoroamidate (NP), 2'-fluoro-
arabino nucleic
acid (FANA), morpholino phosphoroamidate (MF), cyclohexene nucleic acid
(CeNA), and
tricycleDNA (tc-DNA).
In another embodiment of the present invention, the inhibitor may also be
comprised by a
suitable vehicle or carrier. Thus, the present invention also relates to
vehicles and carriers
comprising the composition comprising the inhibitors as described and provided
herein. For
example, in context with the present invention, at least one inhibitor may be
comprised by a
delivery vehicle selected from the group consisting of adeno-associated virus
(AAV), lentiviral
vector, polyethylene imine (PEI), cationic liposomes (e.g. lipid
nanoparticles), silica
nanoparticles, PEGylated PLGA, and neutral lipid. The vehicle of the present
invention may
serve the purpose for assuring the uptake of the composition of the present
invention at the
intended target site in a subject that requires treatment with such a
composition. In context
with the present invention, further exemplary delivery vehicles for an
inhibitor described
herein include lipid (e.g., cationic lipid) containing vehicles (e.g.,
liposomes), viral containing
vehicles (e.g., vectors), polymer containing vehicles (e.g., biodegradable
polymers or
dendrimers), and peptide containing vehicles (e.g., a penetration peptide),
exosomes, and
bacterially-derived, intact minicells. In a specific embodiment of the present
invention, the
delivery vehicle includes more than one compound. For example, it may include
one or more
lipid moieties, one or more peptides, one or more polymers, one or more viral
vectors, or a
combination thereof. Specific embodiments pertain to a delivery vehicle, which
is an
association complex, such as a liposome. A liposome generally includes a
plurality of
components, such as one or more of a cationic lipid (e.g., an amino lipid), a
targeting moiety,
a fusogenic lipid, a PEGylated lipid. In some embodiments, the PEG-lipid may
be a targeted
PEG-lipid. For example, a liposome can include a nucleic acid and an amine-
lipid and a
12
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
PEGylated lipid. In some embodiments of the present invention, the PEG-lipid
is a targeted
PEG-lipid. In further embodiments, the preparation also includes a structural
moiety such as
cholesterol. Most preferred in context of the present invention is a viral
delivery vehicle. The
viral vector may be, e.g., a retrovirus, such as a lentivirus, or an
adenovirus, preferably an
adeno-associated virus (e.g., AAV). Thus, the present invention also provides
a viral vector,
comprising an inhibitor of miR-379 (or a portion or fragment thereof) and miR-
541 (or a
portion or fragment thereof) as described herein, and/or a composition
comprising a viral
vector comprising an inhibitor of miR-379 (or a portion or fragment thereof)
as described
herein and a viral vector comprising an inhibitor of miR-541 (or a portion or
fragment thereof)
as described herein. Where the inhibitors are nucleic acid molecules, their
sequences may
be, e.g., inserted into an untranslated region of a gene, the gene being part
of a construct or
cassette, which is then delivered by the vector. When transduced, a host cell
may express
the sequence of the present invention and therefore silence or express any miR
of the
present invention. The vector may be the viral capsid and may not comprise any
viral or
other polynucleotides, other than the present construct.
As already mentioned, the inhibitor of the composition described and provided
herein may be
a nucleic acid molecule. For example, at least one (or all) inhibitor(s) of
miR-379 (or a portion
or fragment thereof) comprise(s) a nucleotide sequence complementary to or
hybridizing
(e.g., under stringent conditions) to miR-379 (or a portion or fragment
thereof), and at least
one (or all) inhibitor(s) of miR-541 (or a portion or fragment thereof)
comprise(s) a nucleotide
sequence complementary to or hybridizing (e.g., under stringent conditions) to
miR-541 (or a
portion or fragment thereof). In one embodiment of the present invention, the
inhibitor of miR-
379 comprises a nucleotide sequence of SEQ ID NO: 3, wherein not more than 5,
4, 3, 2, or
1 nucleotide(s) is/ are substituted. Also, in a further embodiment, not more
than 30, 25, 20,
15, 10, 6 or 5 nucleotides are added compared to SEQ ID NO: 3. For example,
the
nucleotides, which are added or substituted compared to SEQ ID NO: 3 may be
any other
nucleotide, which allows hybridization of the inhibitor to miR-379 as
described herein. In one
embodiment, where nucleotides are added to SEQ ID NO: 3, such added
nucleotides are
added in such a manner to further increase hybridization to a nucleic acid
sequence
according to SEQ ID NO: 1. For example, up to 5, 4, 3, 2, or 1 nucleotide(s)
is/ are added to
the 5'-end of SEQ ID NO: 3, e.g., 5'-CCUTC-3' or any subset of nucleotides
thereof. In a
specific embodiment of the present invention, the inhibitor of miR-379 is a
nucleic acid
molecule having the sequence of SEQ ID NO: 3.
13
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
In a further embodiment of the present invention, the inhibitor of miR-541
comprises a
nucleotide sequence of SEQ ID NO: 4, wherein not more than 5, 4, 3, 2, or 1
nucleotide(s)
is/ are substituted. Also, in a further embodiment, not more than 30, 25, 20,
15, 10, 9 or 8
nucleotides are added compared to SEQ ID NO: 4. For example, the nucleotides,
which are
added or substituted compared to SEQ ID NO: 4 may be any other nucleotide,
which allows
hybridization of the inhibitor to miR-541 as described herein. In one
embodiment, where
nucleotides are added to SEQ ID NO: 4, such added nucleotides are added in
such a
manner to further increase hybridization to a nucleic acid sequence according
to SEQ ID NO:
2. For example, up to 8, 7, 6, 5, 4, 3, 2, or 1 nucleotide(s) is/ are added to
the 5'-end of SEQ
ID NO: 4, e.g., 5'-TGUGUGTC-3' or any subset of nucleotides thereof. In a
specific
embodiment of the present invention, the inhibitor of miR-541 is a nucleic
acid molecule
having the sequence of SEQ ID NO: 4.
In a further embodiment of the composition of the present invention, the
inhibitor of miR-379
or a portion or fragment thereof comprises a nucleotide sequence of SEQ ID NO:
3, wherein
not more than 5 nucleotides are substituted, and/or the inhibitor of miR-541
or a portion or
fragment thereof comprises a nucleotide sequence of SEQ ID NO: 4, wherein not
more than
nucleotides are substituted.
The present invention also relates to pharmaceutical compositions comprising a
composition
and/or a vehicle or carrier comprising such composition as described and
provided herein.
The present invention also relates to a composition, a vehicle or carrier,
and/or a
pharmaceutical composition as described and provided herein, for use in
treating or
preventing a metabolic dysfunction, disease or disorder related to lipid
(e.g., triglyceride) and
sugar (e.g., glucose) metabolism, and/or related to cancer. In one embodiment
of the present
invention, such metabolic dysfunction, disease or disorder may comprise
glucocorticoid
hormone driven metabolic dysfunction, obesity, diabetes (type 1 and 2),
diabesity, metabolic
syndrome, insulin resistance, hyperglycemia, (systemic) dyslipidemia,
Cushing's syndrome,
adverse or side effects associated with or caused by glucocorticoid (GC)
treatment or
excess, atherosclerosis, heart disease, stroke, (cancer) cachexia, growth
defects, hepatic
steatosis, NASH, and liver fibrosis. In context with the present invention,
the composition,
vehicle or carrier, and/or pharmaceutical composition as described and
provided herein may
also be for use in (personal) diabetes type 1 and/or 2 therapy. In a further
embodiment of the
present invention, such cancer to be treated as described herein may comprise
hepatocellular carcinoma HOC and tumors that have been shown to be correlated
with
14
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
metabolic dysfunction, e.g. obesity, including pancreatic cancer, colon
cancer, endometrial
cancer, breast cancer, esophageal cancer, and gastric cancer.
The embodiments, which characterize the present invention, are described
herein, shown in
the Figures, illustrated in the Examples, and reflected in the claims.
It must be noted that as used herein, the singular forms "a", "an", and "the",
include plural
references unless the context clearly indicates otherwise. Thus, for example,
reference to "a
reagent" includes one or more of such different reagents and reference to "the
method"
includes reference to equivalent steps and methods known to those of ordinary
skill in the art
that could be modified or substituted for the methods described herein.
Unless otherwise indicated, the term "at least" preceding a series of elements
is to be
understood to refer to every element in the series. Those skilled in the art
will recognize, or
be able to ascertain using no more than routine experimentation, many
equivalents to the
specific embodiments of the invention described herein. Such equivalents are
intended to be
encompassed by the present invention.
The term "and/or", wherever used herein, includes the meaning of "and", "or"
and "all or any
other combination of the elements connected by said term".
The term "about" or "approximately" as used herein means within 20%,
preferably within
10%, more preferably within 5%, and most preferably within 3% of a given value
or range.
Throughout this specification and the claims which follow, unless the context
requires
otherwise, the word "comprise", and variations such as "comprises" and
"comprising", will be
understood to imply the inclusion of a stated integer or step or group of
integers or steps but
not the exclusion of any other integer or step or group of integer or step.
When used herein
the term "comprising" can be substituted with the term "containing" or
"including" or
sometimes when used herein with the term "having".
When used herein "consisting of" excludes any element, step, or ingredient not
specified in
the claim element. When used herein, "consisting essentially of" does not
exclude materials
or steps that do not materially affect the basic and novel characteristics of
the claim.
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
Unless specifically stated otherwise, in each instance herein any of the terms
"comprising",
"consisting essentially of' and "consisting of" may be replaced with either of
the other two
terms. For example, where a given feature, compound or range is indicted as
"comprised by"
a respective broader term, such broader term may also "consist of' such
feature, compound
or range.
It should be understood that this invention is not limited to the particular
methodology,
protocols, and reagents, etc., described herein and as such can vary. The
terminology used
herein is for the purpose of describing particular embodiments only, and is
not intended to
limit the scope of the present invention, which is defined solely by the
claims.
All publications and patents cited throughout the text of this specification
(including all
patents, patent applications, scientific publications, manufacturer's
specifications,
instructions, etc.), whether supra or infra, are hereby incorporated by
reference in their
entirety. Nothing herein is to be construed as an admission that the invention
is not entitled to
antedate such disclosure by virtue of prior invention. To the extent, the
material incorporated
by reference contradicts or is inconsistent with this specification, the
specification will
supersede any such material.
The Figures show:
Figure 1: Experimental protocol for the liver-specific inhibition of miR-
541 and miR-379
activity by rAAV-mediated delivery of TuD inhibitors in mice.
Figure 2: Reduction in HOMA-IR (surrogate measurement of insulin
resistance)
observed in animals with hepatic-specific inhibition of miR-541 and miR-379
activity (AAV-TuD, white bar) as compared to negative control (AAV-NC, black
bar).
Figure 3: Decreased circulating levels of triglycerides in animals with
hepatic-specific
inhibition of miR-541 and miR-379 activity (AAV-TuD, white bar) as compared
to negative control (AAV-NC, black bar).
Figure 4: Improvement in glucose clearance following an intraperitoneal
glucose load (2
g/kg) in mice with hepatic-specific inhibition of miR-541 and miR-379 activity
(AAV-TuD, open circles and white bar) as compared to negative control (AAV-
16
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
NC, closed squares and black bar). Glucose profile (A) and area under the
curve (B).
Figure 5: Improvement in glucose tolerance following an intraperitoneal
glucose load
(ipGTT, 2 g glucose/kg) performed on week 4 of therapy in wild-type mice with
combined hepatic-specific inhibition of miR-541 and miR-379 (Figure 5A,
same profile as presented in Figure 4), hepatic-specific inhibition of miR-379
(Figure 5B) or hepatic-specific inhibition of miR-541 activity (Figure 5C)
(AAV-
TuD, open circles in the upper graph and white bars in the lower graph of each
panel) as compared to negative control (AAV-NC, closed squares in the upper
part and black bars in the lower part of each panel). The time-course glucose
profile is presented in the upper graph, while the corresponding area under
the
curve is shown in the lower graph of each panel. A synergistic improvement in
glucose clearance was observed in response to the combined inhibition of
miR-541 and miR-379 activity.
Figure 6: Blood glucose levels in response to an exogenous insulin bolus
(0.7 IU
insulin/kg) intraperitoneally administered on week 3 of therapy to wild-type
mice with combined hepatic-specific inhibition of miR-541 and miR-379 (Figure
6A), hepatic-specific inhibition of miR-379 (Figure 6B) or hepatic-specific
inhibition of miR-541 activity (Figure 6C) (AAV-TuD, open circles in each
Figure 6A-C) as compared to negative control (AAV-NC, closed squares in
each Figure 6A-C). Only in animals carrying hepatic-specific inhibition of
both
miR-541 and miR-379 activity, a significant reduction in glucose levels was
found at all time points studied, as compared to negative control animals.
Figure 7: Plasma triglyceride levels (5-6 h fasting) 2, 3 and 4 weeks after
treatment in
wild-type mice with combined hepatic-specific inhibition of miR-541 and miR-
379 (Figure 7A), hepatic-specific inhibition of miR-379 (Figure 7B) and
hepatic-specific inhibition of miR-541 activity (Figure 7C) (AAV-TuD, white
bars) as compared to negative control (AAV-NC, black bars). A robust
lowering effect of circulating triglycerides was observed in response to the
combined hepatic-specific inhibition of miR-541 and miR-379 activity.
The following sequences are provided herein:
17
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
SEQ ID NO: 1
RNA H. sapiens
miR-379-5p
bold: complementary sequence to inhibitor SEQ ID NO: 3
5"-UGGUAGACUAUGGAACGUAGG-3"
SEQ ID NO: 2
RNA H. sapiens
miR-541-5p
bold: complementary sequence to inhibitor SEQ ID NO: 4
5'-AAAGGAUUCUGCUGUCGGU000ACU-3'
SEQ ID NO: 3
DNA artificial
Inhibitor of miR-379
5'-GTTCCATAGTCTACC-3'
SEQ ID NO: 4
DNA artificial
Inhibitor of miR-541
5'-CGACAGCAGAATCCTT-3'
SEQ ID NO: 5
RNA artificial
Inhibitory sequence to miR-379 and miR-541 comprised by TuD
5'-GACGGCGCUA GGAUCAUCAA CAGUGGGACC GACAGCAUCU AGAAUCCUUU
CAAGUAUUCU GGUCACAGAA UACAACCCUA CGUUCCAAUC UUAGUCUACC
ACAAGAUGAU CCUAGCGCCGUC-3'
The invention is further illustrated by the following examples, however,
without being limited
to the example or by any specific embodiment of the examples.
18
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
Examples
Levels of expression of different microRNAs belonging to the DIk1-Dio3 locus
were
determined by semiquantitative real-time PCR using TaqMan microRNA assays in
liver
biopsies from healthy volunteers (n=10) and obese subjects (n=37) who were not
on
diabetes medications. A consistent upregulation of the microRNAs examined (miR-
127, miR-
337, miR-379, miR-382, miR-134, miR-541, miR-409) was observed in the liver
samples from
obese subjects. The two microRNAs showing the highest increments in their
expression
were miR-379 and miR-541. Significant correlations between the levels of
expression of
these transcripts and different metabolic indicators were detected, as shown
for miR-541 in
Table 1.
The impact of hepatic miR-541 and miR-379 activity inhibition for metabolism
was studied in
vivo by the rAAV-delivery of tough decoy (TuD) inhibitors under the control of
the hepatic-
specific LP1 promoter. Generation of the construct delivered by the AAVs were
carried out
according to Rose AJ etal. Cell Metab 2011,14(1): 123-30. Briefly, to clone
these inhibitors
into the construct delivered by the rAAV vector, the negative control sequence
from the
original vector was replaced by the tough decoy sequence using BglIl and Sall
restriction
enzymes. These inhibitor types were previously demonstrated to strongly
inhibit the activity
of their target microRNAs in vitro (unpublished observations). In three
separate studies of the
inventors of the present invention, C57BL/6J mice (12 animals per group) were
administered
with AAVs (5x1011 viral genomes per mouse) expressing a negative control
sequence or the
tough decoy inhibitor against both miR-541 and miR-379 (study 1, sequence
according to
SEQ ID NO: 5), a negative control sequence or the tough decoy inhibitor
against miR-379
(study 2), and a negative control sequence or the tough decoy inhibitor
against miR-541
(study 3). Body weight as well as food and water intake were monitored
regularly, ipGTTs (2
g glucose/kg) were conducted 2 and 4 weeks after virus administration, while
an ITT (0.7
Ill/kg) was performed 3 weeks after the onset of the study, in both cases
after fasting the
animals for 6 h prior to the tests, which started between 14:00-15:00 h (a
schematic
representation of the experimental protocol is depicted in Figure 1). In
addition, postprandial
blood samples were collected at 23:00 h on weeks 2.5 and 4.5. The experiments
were
terminated 5 weeks after the administration of the viral vectors, half of the
animals (n=6 mice
per group) were killed at 14:00 h after a 5-6 h fasting, while the other half
were killed at 23:00
h during the postprandial state. In study 1, no differences on body weight,
food or water
intake were detected between the animals receiving the negative control
sequence and the
animals carrying the combined hepatic-specific inhibition of miR-541 and miR-
379 activity
19
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
(AAV-TuD). Fasting glucose was significantly lower in the AAV-TuD group from
week 2 till
the end of the study, while fasting insulin concentrations were significantly
reduced from
week 3, and hepatic insulin resistance, as estimated by the homeostatic model
assessment
(HOMA-IR) index, which is calculated from fasting plasma insulin (FPI) and
fasting plasma
glucose (FPG) concentrations [FPI (mU/1) x FPG (mmo1/1)/ 22.5], was found to
be significantly
lower in the AAV-TuD group from week 2 till termination (Figure 2). In
addition, plasma
triglyceride levels were also significantly reduced in this group
irrespectively of the feeding
conditions of the animals (Figures 3 and 7A). Glucose clearance was also
significantly better
in the AAV-TuD group (60% improvement in week 4, p < 0.001; Figures 4A, 4B and
5A).
Despite a significant improvement in glucose clearance was also observed in
the animals
receiving the other two tough decoy inhibitors tested, the effect was less
pronounced (14%
and 36% improvement in response to the single tough decoys against miR-379,
Figure 5B,
and miR-541 activity, Figure 50, respectively), indicating a synergistic
effect in response to
the simultaneous inhibition of both microRNAs. Moreover, the combined
inhibiton of both
microRNAs also induced a remarkable potentiation of the glucose-lowering
effect in
response to an exogenous bolus of insulin, with significantly (p <0.001)
reduced glucose
levels as compared to negative control that were sustained over a two hour
period (Figure
6A). Again, this effect was not matched by the single inhibition of either of
the two
microRNAs (Figures 6B and 6C). Blood glucose levels were determined by glucose
meter
(Accu-Check). Triglyceride levels were measured by enzymatic assay (Sigma-
Aldrich), while
insulin levels were quantified by ELISA (Alpco). The area under the curve of
the glucose
profile in response to an intraperitoneal glucose load (2 g/ kg) was used for
the calculation of
the improvement in glucose clearance.
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
Table 1: shows the correlation between hepatic levels of expression of miR-541
and different
metabolic parameters in healthy volunteers and obese subjects who are not on
diabetes
medications.
miR-541 miR-541 miR-541 miR-541 miR-541 miR-541 miR-541
vs. vs. vs. vs. vs. vs. vs.
insulin HOMA-IR triglycerides ASAT bilirubin leptin HDL
r=0,5495 r=0,5353 r=0,6975 r=0,5485 r=0,6469 r=0,7427 r=-0,4721
p=0,0275 p=0,0326 p=0,0038 p=0,0278 p=0,0068 p=0.0010 ns
The invention is further characterized by the following items:
1. A composition comprising
(a) an inhibitor of miR-379 or a portion or fragment thereof and an
inhibitor of miR-
541 or a portion or fragment thereof, and/or
(b) an inhibitor of the target site of miR-379 or a portion or fragment
thereof and
an inhibitor of the target site of miR-541 or a portion or fragment thereof,
and/or
(c) a combination of an inhibitor of miR-379 or a portion or fragment
thereof and
an inhibitor of the target site of miR-541 or a portion or fragment thereof or
a
combination of an inhibitor of the target site of miR-379 or a portion or
fragment thereof and an inhibitor of miR-541 or a portion or fragment thereof.
2. The composition of item 1, wherein at least one inhibitor of miR-379 or
a portion or
fragment thereof comprises a nucleotide sequence complementary to or
hybridizing to
miR-379 or a portion or fragment thereof, and at least one inhibitor of miR-
541 or a
portion or fragment thereof comprises a nucleotide sequence complementary to
or
hybridizing to miR-541 or a portion or fragment thereof.
3. The composition of item 1 or 2, wherein
21
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
a portion of miR-379 has a nucleotide sequence according to SEQ ID NO: 1,
wherein
not more than 6 nucleotides are substituted, and
a portion of miR-541 has a nucleotide sequence according to SEQ ID NO: 2,
wherein
not more than 8 nucleotides are substituted.
4. The composition of any one of items 1 to 3, wherein at least one
inhibitor comprises a
nucleic acid sequence comprising at least 10 nucleotides.
5. The composition of any one of items 1 to 4, wherein at least one
inhibitor is selected
from the group consisting of Tough Decoys (TuD), Decoys, antisense
oligonucleotides, anti-miR, block-miR, ribozymes, external guide sequence
(EGS),
oligonucleotides, small interference RNA (siRNA), small temporal RNA (stRNA),
short
hairpin RNA (shRNA), small RNA-induced gene activation (RNAa), small
activating
RNA (saRNA), locked nucleic acids (LNA), antagomirs, and peptide nucleic acids
(PNA).
6. The composition of item 5, wherein at least one inhibitor is a Tough
Decoy RNA
(TuD).
7. The composition of any one of items 1 to 6, wherein at least one
inhibitor comprises a
chemical modification of the nucleic acid sequence selected from the group
consisting
of nucleic acid analogs comprising N-acetylgalactosamine (GaINAc),
phosphorothioate DNA (PS), 2'-0-methyl RNA (0Me), 2'-0-methoxy-ethyl RNA
(MOE), peptide nucleic acid (PNA), N3'-P5'-phosphoroamidate (NP), 2'-fluoro-
arabino
nucleic acid (FANA), morpholino phosphoroamidate (MF), cyclohexene nucleic
acid
(CeNA), and tricycleDNA (tc-DNA).
8. The composition of any one of items 1 to 7, wherein at least one
inhibitor is comprised
by a delivery vehicle selected from the group consisting of adeno-associated
virus
(AAV), lentiviral vector, polyethylene imine (PEI), cationic liposomes, silica
nanoparticles, PEGylated PLGA, and neutral lipid.
9. The composition of any one of items 1 to 8, wherein at least one
inhibitor is comprised
by an adeno-associated virus (AAV).
10. The composition of any one of items 1 to 9, wherein
22
CA 03103175 2020-12-09
WO 2020/053186 PCT/EP2019/074056
the inhibitor of miR-379 or a portion or fragment thereof comprises a
nucleotide
sequence of SEQ ID NO: 3, wherein not more than 5 nucleotides are substituted,
and/or
the inhibitor of miR-541 or a portion or fragment thereof comprises a
nucleotide
sequence of SEQ ID NO: 4, wherein not more than 5 nucleotides are substituted.
11. The composition of any one of items 1 to 10, comprising an inhibitor of
miR-379 or a
portion or fragment thereof and an inhibitor of miR-541 or a portion or
fragment
thereof on the same molecule, wherein said molecule comprises a nucleotide
sequence complementary to or hybridizing to miR-379 or a portion or fragment
thereof and a nucleotide sequence complementary to or hybridizing to miR-541
or a
portion or fragment thereof.
12 The composition of item 11, wherein said inhibitor comprises the
nucleotide sequence
of SEQ ID NO: 5, wherein not more than 10 nucleotides are substituted.
13. The composition of any one of items 1 to 12, which is a pharmaceutical
composition.
14. The composition of any one of items 1 to 13 for use in treating or
preventing a
metabolic disease, a disease related to a metabolic disorder, and/or cancer.
15. The composition of item 14, wherein said metabolic disease or disease
related to a
metabolic disorder is selected from the group consisting of glucocorticoid
hormone
driven metabolic dysfunction, obesity, diabetes, diabesity, metabolic
syndrome,
insulin resistance, hyperglycemia, (systemic) dyslipidemia, Cushing's
syndrome,
adverse or side effects associated with or caused by glucocorticoid (GC)
treatment or
excess, atherosclerosis, heart disease, stroke, (cancer) cachexia, growth
defects,
hepatic steatosis, NASH, and liver fibrosis.
23
